[go: up one dir, main page]

ATE304866T1 - Chelatorkonjugate mit verbesserten eigenschaften - Google Patents

Chelatorkonjugate mit verbesserten eigenschaften

Info

Publication number
ATE304866T1
ATE304866T1 AT02745600T AT02745600T ATE304866T1 AT E304866 T1 ATE304866 T1 AT E304866T1 AT 02745600 T AT02745600 T AT 02745600T AT 02745600 T AT02745600 T AT 02745600T AT E304866 T1 ATE304866 T1 AT E304866T1
Authority
AT
Austria
Prior art keywords
improved properties
chelator conjugates
radiometal
conjugates
chelator
Prior art date
Application number
AT02745600T
Other languages
English (en)
Inventor
Colin Mill Archer
Harry John Wadsworth
Torgrim Amersham Engell
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of ATE304866T1 publication Critical patent/ATE304866T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
AT02745600T 2001-07-10 2002-07-10 Chelatorkonjugate mit verbesserten eigenschaften ATE304866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates
PCT/GB2002/003168 WO2003006070A2 (en) 2001-07-10 2002-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
ATE304866T1 true ATE304866T1 (de) 2005-10-15

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745600T ATE304866T1 (de) 2001-07-10 2002-07-10 Chelatorkonjugate mit verbesserten eigenschaften

Country Status (20)

Country Link
US (2) US7597875B2 (de)
EP (1) EP1404377B1 (de)
JP (1) JP5015409B2 (de)
KR (1) KR100892009B1 (de)
CN (4) CN101537190A (de)
AT (1) ATE304866T1 (de)
AU (1) AU2002317317B2 (de)
BR (1) BR0210965A (de)
CA (1) CA2450690C (de)
DE (1) DE60206272T2 (de)
DK (1) DK1404377T3 (de)
ES (1) ES2250671T3 (de)
GB (1) GB0116815D0 (de)
HU (1) HU228850B1 (de)
IL (1) IL159388A0 (de)
MX (1) MXPA04000210A (de)
NO (1) NO334093B1 (de)
RU (1) RU2298012C2 (de)
WO (1) WO2003006070A2 (de)
ZA (1) ZA200400143B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379885A4 (de) * 2001-01-05 2005-07-06 Univ Duke Kontrastverstärkungsmittel für die magnetresonanzabbildung
IL159310A0 (en) * 2001-07-10 2004-06-01 Amersham Health As Peptide-based compounds
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
EP1699495A2 (de) 2003-11-06 2006-09-13 Amersham Health AS Konjugate von angiotensin ii und einem bildgebenden teil
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
WO2005084715A2 (en) * 2004-03-04 2005-09-15 Ge Healthcare As Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
CA2586621A1 (en) 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
ES2380680T3 (es) * 2005-06-08 2012-05-17 Ge Healthcare Limited Procedimiento de uso de monóxido de carbono [11C] en la síntesis de marcaje interno de ésteres marcados con 11C mediante carbonilación fotoinducida de radicales libres sensitizados
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
DE602007012208D1 (de) 2006-02-15 2011-03-10 Ge Healthcare As Kontrastmittel
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
PL2101826T3 (pl) * 2006-12-11 2010-11-30 Ge Healthcare As Znakowane izotopowo związki na bazie peptydów i ich zastosowania
ES2712881T3 (es) 2008-12-02 2019-05-16 Univ Melbourne Conjugados macrocíclicos que contienen nitrógeno como radiofármacos
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
DK2598175T3 (da) 2010-07-27 2020-08-03 Serac Healthcare Ltd Radiofarmaceutiske sammensætninger
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
US20150374861A1 (en) * 2013-02-15 2015-12-31 Thomas Jefferson Unversity Kit for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
PT3131585T (pt) 2014-03-19 2020-10-23 Univ Zuerich Agentes quelantes bifuncionais multidentados para complexação de radionuclídeos em diagnóstico e terapia
JP7495126B2 (ja) 2018-05-08 2024-06-04 ユニヴァーシティー オブ マイアミ 組織への治療用核酸の送達のための材料および方法
CA3100235A1 (en) 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
WO1995004552A2 (en) * 1993-08-04 1995-02-16 Amersham International Plc Radiometal complexes that localise in hypoxic tissue
DE69526203T2 (de) * 1994-01-12 2002-11-28 Amersham Plc, Little Chalfont Biologische zielgerichtete mittel
CN1035997C (zh) * 1994-01-12 1997-10-01 勃勒柯国际有限公司 配位体及其金属配合物
JP4199420B2 (ja) * 1998-05-15 2008-12-17 ジーイー・ヘルスケア・リミテッド 標識化グルタミンおよびリジンアナログ
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
US6988794B2 (en) * 2001-03-08 2006-01-24 Matsushita Electric Industrial Co., Ltd. Inkjet recording ink, method for producing said ink, and ink cartridge and recording device having said ink

Also Published As

Publication number Publication date
HUP0401265A2 (hu) 2004-09-28
ZA200400143B (en) 2004-12-29
JP2005500325A (ja) 2005-01-06
CN101537190A (zh) 2009-09-23
WO2003006070A2 (en) 2003-01-23
US8852550B2 (en) 2014-10-07
KR20040017287A (ko) 2004-02-26
DE60206272T2 (de) 2006-07-13
DK1404377T3 (da) 2006-01-30
HK1064585A1 (en) 2005-02-04
HU228850B1 (en) 2013-06-28
EP1404377B1 (de) 2005-09-21
BR0210965A (pt) 2004-06-08
NO334093B1 (no) 2013-12-09
CN101538313A (zh) 2009-09-23
US20040258619A1 (en) 2004-12-23
NO20035597D0 (no) 2003-12-16
WO2003006070A3 (en) 2003-08-21
EP1404377A2 (de) 2004-04-07
KR100892009B1 (ko) 2009-04-07
HUP0401265A3 (en) 2005-11-28
JP5015409B2 (ja) 2012-08-29
NO20035597L (no) 2004-03-03
DE60206272D1 (de) 2005-10-27
CN100509061C (zh) 2009-07-08
CN1527727A (zh) 2004-09-08
RU2298012C2 (ru) 2007-04-27
CA2450690C (en) 2009-03-24
US7597875B2 (en) 2009-10-06
IL159388A0 (en) 2004-06-01
CA2450690A1 (en) 2003-01-23
CN101607913A (zh) 2009-12-23
RU2003137592A (ru) 2005-05-20
US20100040542A1 (en) 2010-02-18
MXPA04000210A (es) 2004-07-23
AU2002317317B2 (en) 2005-11-17
ES2250671T3 (es) 2006-04-16
GB0116815D0 (en) 2001-08-29
CN101607913B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
ATE304866T1 (de) Chelatorkonjugate mit verbesserten eigenschaften
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
ECSP034600A (es) Compuestos de lactama
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE60213276D1 (de) 1,2,4-thiadiazoliumverbindungen als melanocortinrezeptor-modulatoren
BR0216099B1 (pt) "conjunto de desgaste".
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
IL181529A (en) A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug
DE50204688D1 (de) N-alkylaziridinoprepolymere als dentalmasse
TR200003389T2 (tr) 2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri.
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
TR199901017A2 (xx) B�cek ilac� terkibi.
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ATE242763T1 (de) Methoximinophenylessigsäureamide
ITTO20020744A1 (it) Composizione.
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITTO20020745A1 (it) Composizione.
FR2845696B1 (fr) Non-tisses microfibreux, complexes les incorporant, preparations
TR200102093T2 (tr) Organ koruyucu çözeltiler
UA86379C2 (ru) Азотосодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
HN1999000157A (es) 1,2,3 tetrahidroquinolinas 2 - sustituidas 4 - amino sustituidas.
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить
MY143246A (en) Triazole substituted aminobensophenone compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1404377

Country of ref document: EP